Clinical studyA comparison of cilostazol and pentoxifylline for treating intermittent claudication☆
Section snippets
Material and methods
Design of this trial followed the recommendations of the Society for Vascular Surgery for trials of medications treating intermittent claudication (7). The study was conducted under an Investigational New Drug Exemption with approval of each of the 54 participating institutions’ human subjects review committees and the written informed consent of each participant.
Patients with stable, moderate-to-severe symptoms of intermittent claudication were studied. Symptoms must have been present for at
Results
We screened 922 consenting patients, of whom 699 (76%) met the inclusion criteria and were randomly assigned to one of the three treatments (Figure 1). One patient withdrew before taking the first drug dose, leaving 698 patients who could be evaluated. There were no statistically significant differences in the baseline characteristics of the three groups (Table 1). Of the 698 patients who started treatment, 159 (23%) withdrew from the study before the last visit (week 24). Withdrawal rates
Discussion
Standard medical management of patients with intermittent claudication from atherosclerotic peripheral artery disease includes a walking exercise program, smoking cessation, antiplatelet therapy, treatment of atherosclerosis risk factors, evaluation for associated cardiovascular disease (such as coronary artery disease), and, in some patients, drug treatment for symptomatic relief. Surgical or endovascular intervention is usually reserved for patients with severe, lifestyle-limiting symptoms
Acknowledgements
The following institutions and persons contributed to the Claudication Treatment Study. Wilford Hall Medical Center: DL Dawson; University of Massachusetts Medical Center: BS Cutler; Jobst Vascular Center: HG Beebe; Baylor College of Medicine: JA Herd; Chicago Center for Clinical Research: M Davidson; Jacksonville Cardiovascular Clinic: DA Chinoy; Ochsner Clinic: SR Money; University of Colorado Health Sciences Center: JG Regensteiner; Definitive Health: T Bajwa; University of Virginia: DW
References (22)
- et al.
Proposed design for a double blinded trial to evaluate medications for treatment of intermittent claudication
J Vasc Surg
(1992) - et al.
Suggested standards for reports dealing with lower extremity ischemia
J Vasc Surg
(1986) - et al.
Pentoxifylline efficacy in the treatment of intermittent claudicationmulticenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
Am Heart J
(1982) - et al.
Prevalence of intermittent claudication and its effect on mortality
Acta Med Scand
(1982) - et al.
Diagnosis and treatment of chronic arterial insufficiency of the lower extremitiesa critical review
Circulation
(1996) - et al.
Cilostazol has beneficial effects in treatment of intermittent claudicationresults from a multicenter, randomized, prospective, double-blind trial
Circulation
(1998) - et al.
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
J Vasc Surg
(1998) - et al.
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication
Arterioscleros Thromb Vasc Biol
(1998) - et al.
A new pharmacological treatment for intermittent claudicationresults of a randomized, multicenter trial
Arch Intern Med
(1999) - et al.
The evaluation of exercise performance in patients with peripheral vascular disease
J Cardiopulm Rehab
(1988)
Cited by (388)
Editor's Choice – European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication
2024, European Journal of Vascular and Endovascular SurgeryCilostazol induces vasorelaxation through the activation of the eNOS/NO/cGMP pathway, prostanoids, AMPK, PKC, potassium channels, and calcium channels
2023, Prostaglandins and Other Lipid MediatorsPeripheral Artery Disease: A Comprehensive Updated Review
2022, Current Problems in CardiologyCarnosine as a potential therapeutic for the management of peripheral vascular disease
2022, Nutrition, Metabolism and Cardiovascular DiseasesCilostazol and Tocopherol in the Management of Medication-Related Osteonecrosis of the Jaw: New Insights From a Case Report
2021, Journal of Oral and Maxillofacial SurgeryCitation Excerpt :Besides, when these events are observed, they are usually mild to moderate and self-limiting and do not seem to interfere with the dropout rate.13 In comparison to PEN, previous studies did not show a difference in the incidence of serious adverse events with cilostazol.13,14 There are no definitive therapeutic protocols established for the use of cilostazol in the treatment of MRONJ.
Medical Management of Peripheral Artery Disease
2021, Cardiology Clinics
- ☆
Supported by Otsuka America Pharmaceuticals, Inc., a US affiliate of the manufacturer of cilostazol. The views expressed herein are those of the authors and do not reflect the official policy of the Department of Defense, the Department of Veterans Affairs, or other departments of the United States government.